DysbiosisNCT07231003
The Effect of Glucomannan Powder on Improving Gut Microbiota.
A study testing Glucomannan in people with Dysbiosis, run by Taipei Medical University at 1 site in Taiwan.
Trial summary
The object of this study is evaluating the effects of the Glucommanan on the healthy human subjects who are. In this trial, at most 30 healthy subjects whose ages are 20~65 years old (15 for placebo and 15 for intervention)will be included. Read more about this study
- Who is it for?
- Ages 20 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Dysbiosis
- What is being tested?
- Glucomannan
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 30 participants
- Where
- 1 siteTaiwan
- Study dates
- 28 Aug 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Both genders, aged between 20 and 65 years.
- No history of gastrointestinal disorders or other significant health issues.
- Overall good health.
Who cannot join
- Participants who have taken antibiotics or any medications/supplements that could affect the gut microbiota within 1 week prior to the experiment or during the study.
- Pregnant or breastfeeding women.
- Smokers or individuals with excessive alcohol consumption.
- Chronic disease medication usage for less than 3 months.
- Postmenopausal women on hormone replacement therapy.
- Individuals with acute illnesses such as a cold.
Trial locations and contacts
1 site in 1 country.
About this study
The object of this study is evaluating the effects of the Glucommanan on the healthy human subjects who are. In this trial, at most 30 healthy subjects whose ages are 20~65 years old (15 for placebo and 15 for intervention)will be included. The total experiment will be 9 weeks and the intervention period will be 6 weeks, within which, at week 0, 6, and 7, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST, also known as GOT), alanine aminotransferase (ALT, also known as GPT), blood urea nitrogen (BUN), serum creatinine (Cr), fasting blood glucose (Glucose, AC) and adiponectin would be measured. Feces samples and anthropometric data will also be acquired. The results will be analyzed according to the methods published by the Ministry of Health and Welfare of Taiwan Food and Drug Administration.
- Conditions
- Dysbiosis
- Being tested
- Glucomannan, Placebo
- Keywords
- dysbiosis, Glucomannan, gut-microbiota
- Medical subject headings
- Dysbiosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GlucomannanDietary supplement
2 packs of glucomannan, 2 grams per pack
PlaceboDietary supplement
2 packs of corn starch, 2 grams per pack
| Study group | Role | What they receive |
|---|---|---|
| Placebo group | Placebo comparator | 2 packs of corn starch daily Receives: Dietary Supplement: Placebo |
| Intervention group | Experimental | 2 packs of glucomannan powder daily Receives: Dietary Supplement: Glucomannan |
What is being measured
The primary outcome is the main question the study is designed to answer.
gut microbiota
Evaluation of Gut Microbiota by Analysis of Four Indicator Strains and 16S rRNA Sequencing Using Fecal Samples
Measured: Week(0) (Baseline), Wk(6),Wk7
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Nov 2025
- Study start28 Aug 2025
- Primary completion31 Aug 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DysbiosisStudies of the same condition, open and under way.
- More trials run by Taipei Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Taipei Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07231003
- Sponsor's protocol ID
- lin5611_03
- Status last verified
- Nov 2025
- First submitted
- 13 Nov 2025
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Glucomannan Powder on Improving Gut Microbiota.
- ClinicalTrials.gov ID
- NCT07231003
- Acronym / sponsor ID
- lin5611_03
- Conditions
- Dysbiosis
- Keywords
- dysbiosis, Glucomannan, gut-microbiota
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Taipei Medical UniversityUniversity, hospital or other
- Study start
- 28 Aug 2025 (actual)
- Primary completion
- 31 Aug 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 17 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The object of this study is evaluating the effects of the Glucommanan on the healthy human subjects who are. In this trial, at most 30 healthy subjects whose ages are 20~65 years old (15 for placebo and 15 for intervention)will be included. The total experiment will be 9 weeks and the intervention period will be 6 weeks, within which, at week 0, 6, and 7, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), aspartate aminotransferase (AST, also known as GOT), alanine aminotransferase (ALT, also known as GPT), blood urea nitrogen (BUN), serum creatinine (Cr), fasting blood glucose (Glucose, AC) and adiponectin would be measured. Feces samples and anthropometric data will also be acquired. The results will be analyzed according to the methods published by the Ministry of Health and Welfare of Taiwan Food and Drug Administration.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo group | Placebo comparator | Dietary Supplement: Placebo2 packs of corn starch daily |
| Intervention group | Experimental | Dietary Supplement: Glucomannan2 packs of glucomannan powder daily |
Who may qualify
- Ages
- 20 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Both genders, aged between 20 and 65 years.
- No history of gastrointestinal disorders or other significant health issues.
- Overall good health.
Key exclusion criteria (6 listed)
- Participants who have taken antibiotics or any medications/supplements that could affect the gut microbiota within 1 week prior to the experiment or during the study.
- Pregnant or breastfeeding women.
- Smokers or individuals with excessive alcohol consumption.
- Chronic disease medication usage for less than 3 months.
- Postmenopausal women on hormone replacement therapy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Glucomannan2 packs of glucomannan, 2 grams per pack | Dietary supplement | Intervention group |
| Placebo2 packs of corn starch, 2 grams per pack | Dietary supplement | Placebo group |
Primary outcome
gut microbiota
Time frame: Week(0) (Baseline), Wk(6),Wk7
Evaluation of Gut Microbiota by Analysis of Four Indicator Strains and 16S rRNA Sequencing Using Fecal Samples
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2025.
- Individual participant dataSharing planned: Undecided
Related trials for Dysbiosis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Enrolling by invitationPhase 2
Herbal Supplement (Biocidin REMOVE) for Bacterial Overgrowth in Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS), Small Intestinal Bacterial Overgrowth Syndrome (SIBO)
RecruitingObservational study
Effects Of Periodontal Therapy In Patients With Inflammatory Bowel Disease
Periodontal Diseases, IBD
Recruiting
Effect of a Probiotic or Postbiotic on Gut Microbiome During Antibiotic Treatment
Microbiome
RecruitingObservational study
Metabolic and Functional Study of γδ T Cells in Critically Ill Patients
Sepsis, Critical Illness
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Glucomannan in people with Dysbiosis, run by Taipei Medical University at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
gut microbiota (time frame: Week(0) (Baseline), Wk(6),Wk7). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025.